This article all but underlines the advantage of a nanoviricide over a traditional vaccine.
"...the latest order will protect against a clade 2.2 strain of H5N1 virus (A/Barheaded goose/Qinghai Lake/01/2005)..."
The clade was first detected and identified in January 2005, clade 2.2 has now gone through 3 more seasons of antigenic drift and recombination. The vaccine may already be ineffective and considering how rapidly H5N1 drifts there could very well be a completely new sub-clade. If/when NNVC's technology is finally proven to and recognized by the highest government authorities, some fraction of that $192 million should come to NNVC to include nanoviricides in the strategic stockpile.
Market Data 
Markets 
AI
